A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma

A Pilot Study of the Adverse Events Caused by the Combined Use of Bevacizumab and Vascular Endothelial Growth Factor Receptor-Targeted Vaccination for Patients with a Malignant Glioma

Anti-angiogenic therapy, targeting vascular endothelial growth factor (VEGF)-A/VEGF receptors (VEGFRs), is beneficial for tumor growth prevention in a malignant glioma. A simultaneous blockade using both bevacizumab (Bev), which targets circulating VEGF-A, and a multi-kinase inhibitor on VEGFRs was...

Full description

Bibliographic Details
Main Authors: Ryota Tamura, Yukina Morimoto, Mizuto Sato, Tetsuro Hikichi, Kazunari Yoshida, Masahiro Toda
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:Vaccines
Subjects:
bevacizumab
VEGF-A
VEGFR
peptide vaccine
adverse event
malignant glioma
Online Access:https://www.mdpi.com/2076-393X/8/3/498

Internet

https://www.mdpi.com/2076-393X/8/3/498

Similar Items